AbCellera Enters into a License Agreement with Everest to Discover Antibody Therapies

 AbCellera Enters into a License Agreement with Everest to Discover Antibody Therapies

Shots:

  • Everest to get the rights to develop & commercialize Abs resulting from the collaboration. AbCellera to receive research payments and is eligible to receive clinical and commercial milestones along with royalties on net sales of products
  • The collaboration will accelerate Everest’s portfolio to discover novel medicines for up to 10 targets across multiple indications by utilizing AbCellera’s AI technology
  • Everest gets a benefit from an operating system that helps to supports many antibody modalities to unlock new target classes and open new disease areas to therapeutic access

Click here to­ read full press release/ article | Ref: Businesswire | Image: AbCellera

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post